

ISO/TS 20399-1:2018-11 (E)

Biotechnology - Ancillary materials present during the production of cellular therapeutic products - Part 1: General requirements

| Contents | | Page |
|---|--|-------------|
| Foreword | | iv |
| Introduction | | v |
| 1 | Scope | 1 |
| 2 | Normative references | 1 |
| 3 | Terms and definitions | 1 |
| 4 | Abbreviated terms | 3 |
| 5 | Considerations | 3 |
| 5.1 | General considerations | 3 |
| 5.2 | Animal-derived components of AM | 3 |
| 5.2.1 | General | 3 |
| 5.2.2 | Levels of ADCF | 3 |
| 5.2.3 | Key considerations in the use of animal-derived components | 4 |
| 5.2.4 | Viral inactivation | 4 |
| 5.3 | Mutual responsibilities for AMs | 4 |
| 5.4 | Example workflow | 5 |
| 6 | Ancillary material requirements | 6 |
| 6.1 | Quality management system | 6 |
| 6.2 | Information on ancillary material products and materials used to produce ancillary materials | 6 |
| Annex A (informative) Example of workflow from AM supplier to AM user | | 7 |
| Annex B (informative) Information on AM products and materials used to produce AM | | 8 |
| Bibliography | | 10 |